AMRI Launches Interactive Drug Discovery Tool, "AMRIDirect".

ALBANY, N.Y. -- Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced the launch of AMRIDirect (www.amridirect.com), a searchable, online database of drug-like compounds for use in drug discovery.

With AMRIDirect, scientists can search hundreds of thousands of off-the-shelf compounds by structure, substructure or physicochemical parameters, then purchase individual compounds in various quantities. Features of AMRIDirect include: 24-hour real time access, confidential inquiries, and the flexibility to modify a request based on previous search results.

AMRIDirect provides on-line access to chemical structures, inventory information and other compound-related data such as analytical QC data and purity levels from AMRI's in-stock database, which is updated daily. The interactive system allows researchers to search calculated physicochemical parameters such as logP, logD, pKa, molecular weight and TPSA values in order to select the right compounds. Scientists can initiate substructure or similarity searches in the database according to their specifications, either by using an embedded drawing tool or by importing structures in Molfile or Smiles format. Users can edit and merge results from multiple searches. An electronic ordering system saves time and ensures fast delivery of compounds. Secure, storable personal settings allow users to see their lists when they return to AMRIDirect.

Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs. For more information, visit www.albmolecular.com.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding AMRIDirect. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.